Neuroendocrine basis of human disease

Annals of the New York Academy of Sciences

Volumn 1038, Issue , 2004, Pages 131-137

  Guillemin, Roger ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Hypothalamus; Neuropeptides; Paracrine secretions; Receptors

Indexed keywords

NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR;

ANXIETY DISORDER; AUTOCRINE EFFECT; CARCINOID; CONFERENCE PAPER; DEPRESSION; DIABETES INSIPIDUS; HUMAN; HYPOTHALAMUS; INFLAMMATION; KALLMANN SYNDROME; NEUROENDOCRINE DISEASE; NONHUMAN; PARACRINE SIGNALING; RHEUMATOID ARTHRITIS;

EID: 17744367460     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1315.021     Document Type: Conference Paper

References (27)

1. DU VIGNEAUD, V. 1955. A trail of sulfa research: from insulin to oxytocin. Nobel lecture. In Nobel Lectures, Chemistry 1942-1962, Elsevier Publishing Co. Amsterdam, the Netherlands.
2. SOKOL, H.W. & H. VALTIN. 1965. Morphology of the neurosecretory system in rats homozygous and heterozygous for hypothalamic diabetes insipidus (Brattleboro strain). Endocrinology 77: 692-700.
3. YEN, S.S.C., R.B. JAFFEE, R.L. BARBIERI, EDS. 1999. Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 4th edit. W.B. Saunders Company, Philadelphia, PA.
4. YEN, S.S.C. 1999. In Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 4th edit. S.S.C. Yen, R.B. Jaffee, R.L. Barbieri, Eds.: 30-80. W.B. Saunders Company, Philadelphia, PA.
5. GUILLEMIN, R., P. BRAZEAU, P. BOHLEN, et al. 1982. Growth-hormone releasing factor from a human pancreatic tumor that caused acromegaly. Science 218: 585-587.
6. SHIMON, I., X. YAN, G.E. TAYLOR, et al. 1997. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel Potential therapy for functional pituitary tumors. J. Clin. Invest. 100: 2386-2392.
7. OLIVEIRA, L.M., S.B. SEMINARA, M. BERANOVA, et al. 2001. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J. Clin. Endocrinol. Metab. 86: 1532-1538.
8. JONES, M.C. 1990. The neurocristopathies: reinterpretation based upon the mechanism of abnormal morphogenesis. Cleft Palate J. 27: 126-140.
9. CHEJFEC, G., S. FALKMER, U. ASKENSTEN, et al. 1988. Neuroendocrine tumors of the gastrointestinal tract. Hol. Res. Pract. 183: 143-154.
10. QUALMAN, S.J., W.R. GREEN, C. BROVALL & B.G. LEVENTHAL. 1986. Neurofibromatosis and associated neuroectodermal tumors: a congenital neurocristopathy. Pediatr. Pathol. 5: 65-78.
11. ALTMAN, J. 2002. Weight in the balance. Neuroendocrinology 76: 131-136.
12. DEWHURST, J. 1980. Royal pseudocyesis. Hist. Med. 8: 12-17.
13. BELANOFF, J.K., B.H. FLORES, M. KALEZHAN, et al., 2001. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21: 516-521.
14. BALE, T.L. & W.W. VALE. 2004. CRF and CRF receptors. Role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44: 525-557.
15. OWENS, M.J. & C.B. NEMEROFF. 1999. Corticotropin releasing factor antagonists in affective disorders. Expert Opin. Investig. Drugs. 8: 1849-1858.
16. BRAZEAU, P., W. VALE, R. BURGUS, et al. 1973. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 179: 77.
17. RAULF, P.J., D. HOYER & C. BRUNS. 1994. Differential expression of five somatostatin receptor subtypes, SSTR 1-5, in the CNS and peripheral tissue. Digestion 55: 46-53.
18. KARALIS, K., G. MASTORAKOS, H. SANO, et al. 1994. Somatostatin analogues suppress the inflammatory reaction in vivo. J. Clin. Invest. 93: 2000-2006.
19. WEINSTOCK, J.V. & D. ELLIOTT. 2000. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur. J. Endocrinol. 143: S15-19.
20. ELLIOT, D.E., J. LI, A.M. BLUM, et al. 1999. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-γ release. Eur. J. Immunol. 29: 2454-2463.
21. COARI, G., M. Di FRANCO, A. IAGNOCOCCO, et al. 1995. Intra-articular somatostatin 14 reduces synovial thickness in rheumatoid arthritis: an ultrasonographic study. Int. J. Clin. Pharmacol. Res. 15: 27-32.
22. KARALIS, K., G. MASTORAKOS, H. SANO, et al. 1995. Somatostatin may participate in the anti-inflammatory actions of glucocorticoids. Endocrinology 136: 4133-4138.
23. KRASSAS, G.E. & G.J. KAHALY. 1999. The role of octreoscan in thyroid eye disease. Eur. J. Endocrinol. 140: 373-375.
24. SCHULZ, S., T. HELMHOLZ, J. SCHMITT, et al. 2002. True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and ss5. Breast Cancer Res. Treat. 72: 221-226.
25. HANSSON, J. & P.A. ABRAHAMSSON. 2001. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann. Oncol. 12: S145-152.
26. ZAPATA, P.D., R.M. ROPERO, A.M. VALENCIA, et al. 2002. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J. Clin. Endocrinol. Metab. 87: 915-926.
27. SWINNY, J.D., D. KALICHARAN, E.H. BLAAUW, et al. 2003. Corticotropin-releasing factor receptor types 1 and 2 are differentially expressed in pre- and post-synaptic elements in the post-natal developing rat cerebellum. Eur. J. Neurosci. 18: 349-362.